JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, our results indicated that the levels of JAK2 gene expression, phosphorylated, and total JAK2 proteins at the time of diagnosis correlated with the presence of CHR and EMR in patients with chronic phase CML treated with 3 months of imatinib.